Related Experiment Videos
Risperidone in the management of disruptive behavior disorders
Gahan J Pandina1, Michael G Aman, Robert L Findling
1Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, New Jersey, USA. GPandina@janus.jnj.com
Journal of Child and Adolescent Psychopharmacology
|September 9, 2006
Summary
Risperidone effectively treats disruptive behavior disorders (DBDs) in children and adolescents, improving aggression and behavioral symptoms. Studies show it is well-tolerated, but monitoring growth and metabolic parameters is advised.
Area of Science:
- Child and Adolescent Psychiatry
- Pharmacology
- Neuroscience
Background:
- Disruptive behavior disorders (DBDs), including conduct disorder and oppositional-defiant disorder, present significant challenges in pediatric populations.
- Atypical antipsychotics, such as risperidone, are being investigated for their potential in managing severe symptoms associated with DBDs.
- Previous studies suggest risperidone's efficacy in improving disruptive behaviors in children with related disorders.
Purpose of the Study:
- To review recent studies on the efficacy and safety of risperidone in pediatric patients diagnosed with DBDs.
- To evaluate potential safety risks, including movement disorders, prolactin levels, body weight changes, and cognitive function.
- To provide a comprehensive assessment of risperidone as a treatment option for DBDs in youth.
Main Methods:
- Systematic review of recent clinical studies evaluating risperidone in pediatric DBDs.
- Analysis of safety data, including movement disorders, prolactin concentrations, body weight, and cognitive function from short- and long-term studies.
- Synthesis of efficacy and tolerability findings across the evaluated studies.
Main Results:
- Risperidone demonstrated efficacy in improving symptoms such as anger, aggression, self-injury, and disruptive behaviors in pediatric patients with DBDs.
- The medication was generally well-tolerated, with satisfactory safety profiles observed in the reviewed studies.
- Newly completed analyses confirmed the safety and tolerability, with specific attention to potential side effects.
Conclusions:
- Risperidone is an effective and well-tolerated treatment option for children and adolescents suffering from disruptive behavior disorders.
- Careful monitoring of pediatric patients for growth, weight, sexual maturation, and metabolic parameters is recommended during risperidone treatment.
- The findings support the use of risperidone in managing challenging behaviors associated with DBDs in young individuals, balanced with appropriate clinical oversight.
Related Concept Videos
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:30Oppositional Defiant Disorder
A persistent pattern of angry or irritable mood, defiant behavior, or vindictiveness characterizes Oppositional Defiant Disorder (ODD). Symptoms must occur over at least six months, involve interactions with individuals beyond siblings, and meet specific diagnostic criteria to be clinically significant. The disorder affects emotional regulation, social interactions, and behavior, often manifesting early in life and influencing long-term development and functioning.
Diagnostic Criteria and...
Diagnostic Criteria and...
01:15REM Sleep Behavior Disorder
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...